Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.

Authors : Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber Rd, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart-Gebhart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, Mcfadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr
Year : 2021
Journal : N Engl J Med
Volume : 384
Pages : 2394-2405

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis.

Authors : Tagliamento M, Agostinetto E, Bruzzone M, Ceppi M, Saini KS, de Azambuja E, Punie K, Westphalen CB, Morgan G, Pronzato P, Del Mastro L, Poggio F, Lambertini M
Year : 2021
Journal : Crit Rev Oncol Hematol
Pages : 103365

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.

Authors : Zahavi T, Salmon-Divon M, Salgado R, Elkin M, Hermano E, Rubinstein AM, Francis PA, Di Leo A, Viale G, de Azambuja E, Ameye L, Sotiriou C, Salmon A, Kravchenko-Balasha N, Sonnenblick A
Year : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 67

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.

Authors : Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S
Year : 2021
Journal : Expert Opin Biol Ther
Volume : 21
Pages : 945-962

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Authors : Piccart-Gebhart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber Rd, Viale G, Thomssen C
Year : 2021
Journal : J Clin Oncol
Volume : 39
Pages : 1448-1457

Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Authors : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart-Gebhart M
Year : 2021
Journal : Breast Cancer Res Treat
Volume : 185
Pages : 107-116

Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy.

Authors : Caparica R, Amorim L, Amaral P, Uratani L, Muniz D, Hendlisz A, de Azambuja E, Glasberg J, Takahashi TK, Filho EA, Canellas R, Saragiotto D, Sabbaga J, Mak M
Year : 2020
Journal : BMJ Support Palliat Care

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?

Authors : Franzoi MA, de Azambuja E
Year : 2020
Journal : ESMO Open
Volume : 5

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

Authors : Agostinetto E, Caparica R, de Azambuja E
Year : 2020
Journal : ESMO Open
Volume : 5

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.

Authors : Lambertini M, Agbor-Tarh D, Metzger-Filho O, Ponde NF, Poggio F, Hilbers FS, Korde LA, Chumsri S, Werner O, Del Mastro L, Caparica R, Moebus V, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E
Year : 2020
Journal : ESMO Open
Volume : 5

Clinical management of first-line advanced triple-negative breast cancer patients

Authors : Rediti M, Punie K, de Azambuja E, Naert E, Taylor D, Duhoux FP, Denys H, Awada A, Wildiers H, Ignatiadis M
Year : 2020
Journal : Belgian J Medical Oncology
Volume : 14(7)
Pages : 333-338

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

Authors : Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart-Gebhart M, Biganzoli E
Year : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 2883-2891

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.

Authors : Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, de Castro J, Lamba Saini M, Loibl S, Curigliano G, Twelves C, Leone M, Patnaik MM
Year : 2020
Journal : Br J Cancer
Volume : 123
Pages : 694-697

Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?

Authors : Caparica R, de Angelis C, Fêde Â, Werutsky G, de Azambuja E
Year : 2020
Journal : Expert Rev Anticancer Ther
Volume : 20
Pages : 563-573

HER2-positive advanced breast cancer treatment in 2020.

Authors : Cesca MG, Vian L, Cristóvão-Ferreira S, Pondé N, de Azambuja E
Year : 2020
Journal : Cancer Treat Rev
Volume : 88
Pages : 102033

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.

Authors : de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G
Year : 2020
Journal : ESMO Open
Volume : 5

Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials.

Authors : Caparica R, Bruzzone M, Hachem GE, Ceppi M, Lambertini M, Glasberg J, de Azambuja E, Van Laethem JL, Hendlisz A
Year : 2020
Journal : Crit Rev Oncol Hematol
Volume : 149
Pages : 102940

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.

Authors : Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, de Angelis C, Hendlisz A, Awada A, Piccart-Gebhart M, de Azambuja E
Year : 2020
Journal : Breast Cancer Res Treat
Volume : 181
Pages : 199-209

Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.

Authors : Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E
Year : 2020
Journal : Clin Breast Cancer
Volume : 20
Pages : 262-273.e7

Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer.

Authors : Eiger D, Brandão M, de Azambuja E
Year : 2020
Journal : ESMO Open
Volume : 5